article thumbnail

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

PRICE FIGHTS. With some caveats, ICER recommended lower prices. —Merrimack Pharmaceuticals (NASDAQ: MACK ) announced layoffs of 22 percent of its staff and the resignation of CEO Robert Mulroy. . —The Nobel in Chemistry went to three scientists, in France, the Netherlands, and the U.S., CLINICAL NEWS.

article thumbnail

Biotech Roundup: Moonshots, Pink Slips, Gilead, Brexit & More

Xconomy

At the gathering, Biden took verbal shots at scofflaw cancer researchers and at drug prices, while the FDA said it would take a shot at restructuring the way it evaluates oncology products. Gilead Sciences has been a target of drug-price criticism for its hepatitis C treatments, but it dialed back the price of its new one.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More

Xconomy

president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that naming-and-shaming—that is, Congress hauling executives into hearings and penning angry letters—certainly hasn’t done the trick. Speculation swirled this week around the incoming U.S.

News 40
article thumbnail

What’s Next for American Workers as Trade, Automation Roil Manufacturing?

Xconomy

Bloomberg reported that the cuts were a response to lagging stock prices and CEO Mark Fields’s desire to trim company costs this. Read more » Reprints | Share:

Report 55
article thumbnail

Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More

Xconomy

In a week of big personnel moves, none was more surprising than Editas Medicine CEO Katrine Bosley’s departure.

Guide 63
article thumbnail

Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More

Xconomy

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.

Writing 56
article thumbnail

Bio Roundup: Phase 3 Fails, Shkreli Jailed, Moderna Flip-Flops & More

Xconomy

It was a week of realignments. President Trump, who used to be known as “The Donald” but now goes by “ Amnesty Don ,” kept up the parlay-voo with his new friends Chuck and Nancy. Martin Shkreli, who was once known— and still is!